TECH BIO-TECHNE Corp
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 842023 · Fiscal year ends 06/30
Financial factors as of 2026-09-30 (2027Q1), TTM = sum of the last four quarters
Growth
TTM revenue YoY0.9%
TTM net income YoY120.5%
TTM EPS YoY124.5%
Revenue 3-yr CAGR2.4%
Net income 3-yr CAGR-11.3%
Margins
Gross margin65.8%
Operating margin19.6%
Net margin14.0%
FCF margin25.1%
EBITDA margin27.5%
Returns
ROE8.3%
ROA6.7%
ROIC (approx.)9.3%
Asset turnover0.48x
Leverage & solvency
Liabilities / assets17.9%
Debt / equity0.00x
Current ratio2.28x
Interest coverage27.16x
Cash quality & payout
Operating cash flow / net income1.96x
Accruals ratio-6.4%
Payout ratio29.1%
Capex / revenue2.4%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY2026*2026-06-30 | FY20252025-06-30 |
|---|---|---|
| Income statement | ||
| Revenue | $1.22B | $1.22B |
| Cost of revenue | $415.97M | $429.36M |
| Gross profit | $799.07M | $790.27M |
| R&D expense | $94.77M | $99.50M |
| SG&A expense | $452.42M | $588.52M |
| Operating income | $251.89M | $102.25M |
| Interest expense | $9.63M | $8.51M |
| Pretax income | $240.68M | $98.46M |
| Income tax | $58.82M | $25.06M |
| Net income | $181.86M | $73.40M |
| EBITDA | $349.25M | $212.16M |
| EPS (basic) | 1.17 | 0.47 |
| EPS (diluted) | 1.16 | 0.46 |
| Dividends declared per share | 0.32 | 0.32 |
| Weighted avg. shares (diluted) | 157.01M | 159.72M |
| Balance sheet | ||
| Cash & equivalents | $264.71M | $162.19M |
| Receivables | $216.59M | $206.88M |
| Inventory | $195.74M | $189.45M |
| Current assets | $744.40M | $608.30M |
| PP&E, net | $231.84M | $245.72M |
| Goodwill | $975.36M | $980.93M |
| Intangibles | $303.46M | $365.60M |
| Total assets | $2.59B | $2.56B |
| Current liabilities | $163.70M | $175.85M |
| Long-term debt | $200.00M | $346.00M |
| Total debt | $200.00M | $346.00M |
| Total liabilities | $478.50M | $639.06M |
| Shareholders' equity | $2.11B | $1.92B |
| Net debt | -$64.71M | $183.81M |
| Shares outstanding | 156.10M | 154.97M |
| Cash flow statement | ||
| Operating cash flow | $292.07M | $287.56M |
| Capital expenditure | $28.85M | $31.01M |
| Free cash flow | $263.22M | $256.55M |
| Investing cash flow | -$18.19M | -$35.18M |
| Financing cash flow | -$169.11M | -$253.91M |
| Depreciation & amortization | $97.36M | $109.90M |
| Stock-based compensation | $41.37M | $40.83M |
| Dividends paid | $49.92M | $50.39M |
| Share buybacks | $41.67M | $275.73M |
Free plan shows the latest 2 periods; Pro shows all 18 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.